FDA, Rx Antihistamine Makers' Next Move: Compromise?

A negotiated compromise between FDA and the manufacturers of second-generation antihistamines seems the most logical way to resolve the legal, regulatory and financial obstacles facing both sides.

More from Archive

More from Pink Sheet